What Was Approved?
On December 12, 2025, the U.S. Food and Drug Administration approved Lerochol (lerodalcibep-liga) as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
How Does Lerochol Work?
Lerochol is a PCSK9 inhibitor.
PCSK9 promotes breakdown of LDL receptors in the liver. By blocking PCSK9, lerodalcibep allows more LDL receptors to remain available to remove LDL cholesterol from the blood.
How Is Lerochol Given?
The recommended dose is:
300 mg by subcutaneous injection once monthly.
It may be injected into the abdomen or thigh. A caregiver or healthcare professional may also administer it into the upper arm.
What Did the Clinical Trials Show?
FDA approval was supported by three randomized, placebo-controlled trials involving more than 2,300 adults.
Compared with placebo, Lerochol reduced LDL-C by approximately:
- 55% in one 52-week trial
- 50% in another 52-week trial
- 59% in a 24-week HeFH trial
These results describe average trial outcomes and do not guarantee the same LDL-C reduction for every patient.
What Are the Common Side Effects?
Common adverse reactions included:
- Injection-site reactions
- Nasopharyngitis
- Diarrhea
- Nausea
- Peripheral edema
Does Lerochol Replace Diet, Exercise, or Other Cholesterol Medicines?
No.
The FDA-approved indication is as an adjunct to diet and exercise.
In the clinical trials, many participants were also receiving maximally tolerated statin therapy, with or without other lipid-lowering medicines.
Treatment should therefore be individualized according to LDL-C levels, cardiovascular risk, treatment response, and other medications.
Bottom Line
Lerochol (lerodalcibep-liga) is an FDA-approved once-monthly PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including HeFH.
It provides another injectable option for LDL-C reduction, but the appropriate place in therapy should be determined based on the patient’s overall cardiovascular risk and current treatment plan.
Sources
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2025.
- U.S. Food and Drug Administration (FDA) — Drug Trials Snapshot: Lerochol.
- U.S. Food and Drug Administration (FDA) — Lerochol (lerodalcibep-liga) Prescribing Information.